Publications by authors named "Josie K Ward"

Rationale: Heterogeneity of the host response within sepsis, acute respiratory distress syndrome (ARDS) and more widely critical illness, limits discovery and targeting of immunomodulatory therapies. Clustering approaches using clinical and circulating biomarkers have defined hyper-inflammatory and hypo-inflammatory subphenotypes in ARDS associated with differential treatment response. It is unknown if similar subphenotypes exist in sepsis populations where leucocyte transcriptomic-defined subphenotypes have been reported.

View Article and Find Full Text PDF

Background & Aims: AXL and MERTK expression on circulating monocytes modulated immune responses in patients with cirrhosis (CD14HLA-DRAXL) and acute-on-chronic liver failure (CD14MERTK). AXL expression involved enhanced efferocytosis, sustained phagocytosis, but reduced tumor necrosis factor-α/interleukin-6 production and T-cell activation, suggesting a homeostatic function. Axl was expressed on murine airway in tissues contacting the external environment, but not interstitial lung- and tissue-resident synovial lining macrophages.

View Article and Find Full Text PDF
Article Synopsis
  • Myocardial dysfunction is prevalent in sepsis, but a study called the LeoPARDS trial found that the inodilator levosimendan does not improve organ dysfunction or reduce mortality in septic shock patients.
  • The research measured cardiac biomarkers and inflammatory mediators in patients to assess the drug's effects, revealing no benefits in reducing the SOFA score or 28-day mortality rates.
  • Specifically, patients with high NT-proBNP who received levosimendan showed worse SOFA scores compared to those on placebo, indicating that levosimendan added to standard care does not enhance outcomes in septic patients with cardiac dysfunction.
View Article and Find Full Text PDF